

24TH OF MAY

06:00 PM - 09:30 PM UAE TIME
Venue: Emirates Jumeirah Towers - Dubai

Thyroid Eye Disease ADVISORY BOARD GULF

AGENDA

06:00 - 06:10 pm

Introduction and Objectives

Amgen Team

06:10 - 06:45 pm

Thyroid Eye Disease Burden and Disease State

ALL Advisors

- o TED Burden and Disease definition
- o Natural course of the disease, severity and activity measures
- o Current MDT approach between endocrinologists and ocular surgeons in managing TED

06:45 - 07:35 pm

Current TED Management Guidelines and Treatment Approaches

ALL Advisors

- o Treatment paradigms during each TED activity stage
- o International Guidelines recommendations
- o Treatment goals and expectations

07:35 - 07:50 pm

Coffee and Prayer Break

07:50 - 09:15 pm

Teprotumumab Clinical Data

Dr. Habibullah Eatamadi

- o Insights on Teprotumumab clinical trial data (Optic and Optic-x Trial) and real-world experience
- o Teprotumumab safety profile

Workshop: Appropriate TED Patient Profile for Teprotumumab Treatment

ALL Advisors

09:15 - 09:30 pm

Closing Remarks

Amgen Team

- o Stage 2: asynchronous platform orientation
- o Post meeting survey

Moderator: Dr. Khaled AbuHaleeqa

Invited Advisors: Dr. Khaled AbuHaleeqa,

Dr. Habibullah Eatamadi, Dr. Nezzar Hashemi, Dr. Sabreyah AlSaleh, Dr. Adel Albulushi, Dr. Hanan AlKandari, Dr. Vinod Gauba, Dr. Rafic Antonios and Dr. Elsanausi Elzaridi